REG - Solvonis Therapeutic - £1m subscription to accelerate AI drug discovery

Solvonis TherapeuticsAnnouncement

11/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250711:nRSK6425Qa&default-theme=true

RNS Number : 6425Q  Solvonis Therapeutics PLC  11 July 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
11 July 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

£1.0 million subscription by major shareholders to accelerate AI drug
discovery programme

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
announces that it has raised gross proceeds of £1.0 million through a direct
subscription (the "Subscription") for 333,333,334 new ordinary shares of
£0.001 each in the capital of the Company (the "Subscription Shares") at a
price of 0.3 pence per Subscription Share (the "Issue Price"). The Issue Price
is approximately a 3.5% premium to the closing price of 0.29 pence per share
on 10 July 2025.

The Subscription is being undertaken by three of the Company's largest
shareholders, reflecting their continued strong support for Solvonis' strategy
and execution.

Use of proceeds

The net proceeds of the Subscription will be deployed to accelerate Solvonis'
AI supported central nervous system drug discovery programme, which is
initially focused on major depressive disorder and stimulant use disorder,
being two therapeutic areas with significant unmet needs and limited
innovation. The global antidepressant drug market was valued by Global Market
Insights, the global market research and management consulting company
catering to corporations, non-profits, universities, and government agencies,
at approximately £15 billion in 2024. Global Market Insights projects this
to grow at a compound annual growth rate of 7.5% through to 2034. Meanwhile,
stimulant use disorders, such as those related to cocaine and amphetamine
dependence, remain underserved by the pharmaceutical industry, with no
FDA-approved medications currently available, despite the substantial public
health burden they represent (source: U.S. Veterans Affairs Health Services
R&D).

Solvonis is uniquely positioned to address both of these high-burden
conditions through its AI enabled, central nervous system focused R&D
platform. This R&D platform integrates proprietary compound libraries,
predictive modelling and rapid translational tools to drive discovery in areas
traditionally marked by low investment and slow innovation.

The proceeds from the Subscription will enable the Company to accelerate lead
identification and early-stage candidate validation across these two core
therapeutic indications.

Admission and Total Voting Rights

Application will be made for the Subscription Shares to be admitted to trading
on the Main Market of the London Stock Exchange and to listing in the FCA's
Official List Equity Shares (transition) category ("Admission").

It is expected that Admission will become effective and that dealings in the
Subscription Shares will commence at 8.00 a.m. on or around 17 July 2025.

Following Admission, the Company's enlarged issued ordinary share capital will
comprise 6,242,104,024 ordinary shares of £0.001 each. This figure may be
used by shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company under the
FCA's Disclosure Guidance and Transparency Rules.

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "We are
pleased to receive this investment from our largest and longest-standing
shareholders. Their continued conviction supports our strategy to lead
innovation in addiction and mental health therapeutics, including the
acceleration of our proprietary AI-supported discovery platform. This funding
enables acceleration of building a differentiated pipeline in stimulant use
and depressive disorders."

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder ("AUD") and
Post-Traumatic Stress Disorder ("PTSD"), conditions which the Company
estimates affect over 80 million people across the UK, US, and EU4. Its lead
asset, SVN-001, is currently in Phase 3 for severe AUD in the UK and EU.
SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to
severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel
serotonin-dopamine modulators designed to enhance pro-social behaviour and
long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery programme built
on a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUGUMUPAPUU